The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
The company returns high margins, thereby supporting business profitability.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 339.76 USD
Stock prices approach a strong long-term resistance in weekly data at USD 423.57.
The stock is close to a major daily resistance at USD 419.09, which should be gotten rid of so as to gain new appreciation potential.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company benefits from high valuations in earnings multiples.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Sector Advanced Medical Equipment & Technology - NEC